Molecular investigations have led to increased therapeutic options for prostatic adenocarcinoma. A single case report of a PRPSAP1::NTRK3 gene fusion occurring in prostate cancer was previously reported. A review of the literature revealed that NTRK gene rearrangements are exceedingly rare molecular events in prostate cancer. NTRK gene fusions can be oncogenic drivers or develop as resistance mechanisms. The tumor-agnostic approvals of TRK inhibitors by the FDA provide additional rationale for molecular investigations of aggressive prostatic adenocarcinomas. This may prove to be an additional therapeutic option for patients with aggressive prostatic carcinomas refractory to initial therapy. We report a case of an aggressive castrate-resistant prostatic adenocarcinoma with a BMP6::NTRK3 gene fusion.
CroninKAScottSFirthAU, et al.Annual report to the nation on the status of cancer, part 1: national cancer statistics. Cancer. 2022;128(24):4251–4284. doi:https://doi.org/10.1002/cncr.34479
2.
PosdzichPDarrCHilserT, et al.Metastatic prostate cancer-a review of current treatment options and promising new approaches. Cancers (Basel). 2023;15(2):461. doi:https://doi.org/10.3390/cancers15020461
3.
AbidaWArmeniaJGopalanA, et al.Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol. 2017;2017(1):1–16. doi:https://doi.org/10.1200/PO.17.00029
4.
CotterKRubinMA. The evolving landscape of prostate cancer somatic mutations. Prostate. 2022;82(Suppl 1):S13–S24. doi:https://doi.org/10.1002/pros.24353
5.
YehYAYangSConstantinescuM, et al.Prostatic adenocarcinoma with novel NTRK3 gene fusion: a case report. Am J Clin Exp Urol. 2019;7(5):341–345.
6.
RolfoCDrilonAHongD, et al.NTRK1 fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. Br J Cancer. 2022;126(3):514–520. doi:https://doi.org/10.1038/s41416-021-01536-1
7.
IkedaSElkinSKTomsonBNCarterJLKurzrockR. Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. Cancer Biol Ther. 2019;20(2):219–226. doi:https://doi.org/10.1080/15384047.2018.1523849
8.
LingQLiBWuX, et al.The landscape of NTRK fusions in Chinese patients with solid tumor. Ann Oncol.2018;29(Supplement 8):viii22–viii23. doi:https://doi.org/10.1093/annonc/mdy269.073
9.
WestphalenCBKrebsMGLe TourneauC, et al.Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol.2021;5(1):69. doi:https://doi.org/10.1038/s41698-021-00206-y
10.
RosenEYGoldmanDAHechtmanJF, et al.TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations. Clin Cancer Res. 2020;26(7):1624–1632. doi:https://doi.org/10.1158/1078-0432.CCR-19-3165
11.
SolomonJPLinkovIRosadoA, et al.NTRK Fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol.2020;33(1):38–46. doi:https://doi.org/10.1038/S41379-019-0324-7
12.
GatalicaZXiuJSwensenJVranicS. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 2019;32(1):147–153. doi:https://doi.org/10.1038/s41379-018-0118-3
13.
HongDSDuBoisSGKummarS, et al.Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21(4):531–540. doi:https://doi.org/10.1016/S1470-2045(19)30856-3
14.
DrilonALaetschTWKummarS, et al.Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–739. doi:https://doi.org/10.1056/NEJMoa1714448
15.
SchrockABZhuVWHsiehWS, et al.Receptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2018;13(9):1312–1323. doi:https://doi.org/10.1016/j.jtho.2018.05.027
16.
XiaHXueXDingH, et al.Evidence of NTRK1 fusion as resistance mechanism to EGFR TKI in EGFR+ NSCLC: results from a large-scale survey of NTRK1 fusions in Chinese patients with lung cancer. Clin Lung Cancer. 2020;21(3):247–254. doi:https://doi.org/10.1016/j.cllc.2019.09.004
17.
GuptaSShollLMYangY, et al.Genomic analysis of spermatocytic tumors demonstrates recurrent molecular alterations in cases with malignant clinical behavior. J Pathol. 2024;262(1):50–60. doi:https://doi.org/10.1002/path.6210
18.
ZhouXWangJPatelJ, et al.Exploration of coding and non-coding variants in cancer using GenomePaint. Cancer Cell. 2021;39(1):83–95.e4. doi:https://doi.org/10.1016/j.ccell.2020.12.011
19.
MarcusLLemerySJKeeganPPazdurR. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753–3758. doi:https://doi.org/10.1158/1078-0432.CCR-18-4070
20.
ScottRJMehtaAMacedoGSBorisovPSKanesvaranREl MetnawyW. Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions. Oncotarget. 2021;12(16):1600–1614. doi:https://doi.org/10.18632/oncotarget.28015
21.
BentleyHHamdyFCHartKA, et al.Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer. 1992;66(6):1159–1163. doi:https://doi.org/10.1038/bjc.1992.427
22.
YuenHFChanYPCheungWLWongYCWangXChanKW. The prognostic significance of BMP-6 signaling in prostate cancer. Mod Pathol. 2008;21(12):1436–1443. doi:https://doi.org/10.1038/modpathol.2008.94
23.
MitelmanFJohanssonBMertensF. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer.
HechtmanJFBenayedRHymanDM, et al.Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol.2017;41(11):1547–1551. doi:https://doi.org/10.1097/PAS.0000000000000911
